nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
β-adrenoreceptors and the risk of Parkinson's disease
|
Hopfner, Franziska |
|
|
19 |
3 |
p. 247-254 |
artikel |
2 |
Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study
|
Armangue, Thaís |
|
|
19 |
3 |
p. 234-246 |
artikel |
3 |
Breaking boundaries between demyelinating disorders and autoimmune encephalitis
|
Marignier, Romain |
|
|
19 |
3 |
p. 199-200 |
artikel |
4 |
Challenges to stroke care 5 years after endovascular therapy became the standard
|
Goyal, Mayank |
|
|
19 |
3 |
p. 210-211 |
artikel |
5 |
Correction to Lancet Neurol 2020; 19: 247–54
|
|
|
|
19 |
3 |
p. e3 |
artikel |
6 |
Correction to Lancet Neurol 2020; 19: 38–48
|
|
|
|
19 |
3 |
p. e3 |
artikel |
7 |
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
|
Chataway, Jeremy |
|
|
19 |
3 |
p. 214-225 |
artikel |
8 |
Encephalitis—spreading the word
|
Morgan, Jules |
|
|
19 |
3 |
p. 213 |
artikel |
9 |
Essential tremor-plus: a controversial new concept
|
Louis, Elan D |
|
|
19 |
3 |
p. 266-270 |
artikel |
10 |
Essential tremor-plus: a temporary label
|
Vidailhet, Marie |
|
|
19 |
3 |
p. 202-203 |
artikel |
11 |
Feast or famine in multiple sclerosis therapeutics
|
Fox, Robert J |
|
|
19 |
3 |
p. 196-197 |
artikel |
12 |
Health-care disparities for people with multiple sclerosis
|
Laurson-Doube, Joanna |
|
|
19 |
3 |
p. 207-208 |
artikel |
13 |
Issues important to the design of stroke recovery trials
|
Cramer, Steven C |
|
|
19 |
3 |
p. 197-198 |
artikel |
14 |
Leading the way for neuromuscular disorders since 1950
|
The Lancet Neurology, |
|
|
19 |
3 |
p. 195 |
artikel |
15 |
Osmotherapy in traumatic brain injury
|
Rowland, Matthew J |
|
|
19 |
3 |
p. 208 |
artikel |
16 |
Patient-reported outcome measures: the need for new and reliable tools
|
Khajuria, Ankur |
|
|
19 |
3 |
p. 206-207 |
artikel |
17 |
Safety and efficacy of GABAA α5 antagonist S44819 in patients with ischaemic stroke: a multicentre, double-blind, randomised, placebo-controlled trial
|
Chabriat, Hugues |
|
|
19 |
3 |
p. 226-233 |
artikel |
18 |
Subjective cognitive decline: what is it good for?
|
Howard, Robert |
|
|
19 |
3 |
p. 203-204 |
artikel |
19 |
The characterisation of subjective cognitive decline
|
Jessen, Frank |
|
|
19 |
3 |
p. 271-278 |
artikel |
20 |
The global burden of neurological disorders: translating evidence into policy
|
Feigin, Valery L |
|
|
19 |
3 |
p. 255-265 |
artikel |
21 |
The growing burden of neurological disorders in low-income and middle-income countries: priorities for policy making
|
Winkler, Andrea S |
|
|
19 |
3 |
p. 200-202 |
artikel |
22 |
The need for continued care after sponsor closure
|
May, Arne |
|
|
19 |
3 |
p. 205 |
artikel |
23 |
The need for continued care after sponsor closure – Authors' reply
|
Goadsby, Peter J |
|
|
19 |
3 |
p. 205-206 |
artikel |
24 |
The unique and specialised history of Queen Square
|
Koehler, Peter J |
|
|
19 |
3 |
p. 212 |
artikel |
25 |
William Jagust: Arrow Through The Rings
|
Burton, Adrian |
|
|
19 |
3 |
p. 209 |
artikel |